EC Ophthalmology

Editorial Volume 14 Issue 2 - 2023

Current Ophthalmopharmacotherapy Needs: Beyond the Eye

Marianne L Shahsuvaryan*

Professor of Ophthalmology, Yerevan State Medical University, Republic of Armenia

*Corresponding Author: Marianne L Shahsuvaryan, Professor of Ophthalmology, Yerevan State Medical University, Republic of Armenia.
Received: January 29, 2023; Published: January 31, 2023

History of ophthalmopharmacotherapy starts from ancient Egypt documented in the Ebers Papyrus (ca. 1,550 B. C.) [1,2], including “drugs with undeniable pharmacologic activity, such as copper salts, calcium carbonate, sulfur, hyoscyamus, and ricinus reeds” [2]. Topical therapy of the eye diseases was commonly used at that time, dominantly presented by eye ointments with different components and honey [1]. Eye drops were used rarely [1].

A lot has changed since then.

The basics of modern ophthalmological pharmacotherapy were laid in nineteenth century [3].

  1. Andersen SR. “The eye and its diseases in Ancient Egypt”. Acta Ophthalmologica Scandinavica 3 (1997): 338-344.
  2. Heinemann MH. “The History of Ophthalmic Therapeutics”. In: Sears, M.L. (editions) Pharmacology of the Eye. Handbook of Experimental Pharmacology, Springer, Berlin, Heidelberg 69 (1984).
  3. Zayyeni M and Helmstädter A. “Ophthalmic Pharmacotherapy in Nineteenth-Century Germany”. Pharmaceutical Historian 2 (2022): 40-46.
  4. Priesner C Runge. “Friedlieb Ferdinand”. In: Neue Deutsche Biographie 22 (2005): 263-264.
  5. Komatsu Y. “[A history of the development of eye drops used to treat glaucoma]”. Yakushigaku Zasshi 1 (2007): 7-16.
  6. Meghpara BB., et al. “Pilocarpine 1.25% and the changing landscape of presbyopia treatment”. Current Opinion in Ophthalmology 4 (2022): 269-274.
  7. Al-Khersan H., et al. “Retinal detachments associated with topical pilocarpine use for presbyopia”. American Journal of Ophthalmology 242 (2022): 52-55.
  8. Eton EA., et al. “Rhegmatogenous retinal detachment following initiation of pilocarpine hydrochloride ophthalmic solution 1.25% for treatment of presbyopia”. Retinal Cases and Brief Reports (2022): 10-1097.
  9. Esteva de Sagrera J. “Los colirios desde la antigüedad hasta el siglo XIX [Eye-drops from olden times to the XIXth century]”. Medical History 3 (2015): 4-25.
  10. Tian B., et al. “Ocular Drug Delivery: Advancements and Innovations”. Pharmaceutics 9 (2022): 1931.
  11. Awwad S., et al. “Principles of pharmacology in the eye”. British Journal of Pharmacology 23 (2017): 4205-4223.
  12. Wang TZ., et al. “Engineering Advanced Drug Delivery Systems for Dry Eye: A Review”. Bioengineering1 (2022): 53.
  13. Chen X., et al. “Research Progress of Bioinspired Nanostructured Systems for the Treatment of Ocular Disorders”. Pharmaceuticals 1 (2023): 96.
  14. Porta M and Striglia E. “Intravitreal anti-VEGF agents and cardiovascular risk”. Internal and Emergency Medicine 2 (2020): 199-210.
  15. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study”. The Lancet Global Health 2 (2021): e130-e143.
  16. Pascolini D and Mariotti SP. “Global estimates of visual impairment: 2010”. British Journal of Ophthalmology 5 (2012): 614-618.
  17. Strengthening diagnosis and treatment of diabetic retinopathy in the South-East Asia Region. New Delhi: World Health Organization, Regional Office for South-East Asia; Licence: CC BY-NC-SA 3.0 IGO (2020).
  18. Tham YC., et al. “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis”. Ophthalmology11 (2014): 2081-2090.

Marianne L Shahsuvaryan. Current Ophthalmopharmacotherapy Needs: Beyond the Eye. EC Ophthalmology 14.2 (2023):34-36.